Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: Post-hoc analyses of a randomized, double-blind clinical trial

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Bossie, Cynthia A ^a   Sliwa, Jennifer K ^a   Ma, Yi Wen ^b   Fu, Dong Jing ^a   Alphs, Larry ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PALIPERIDONE; PLACEBO; ISOXAZOLE DERIVATIVE; PALMITIC ACID DERIVATIVE;

ADULT; AGITATION; AKATHISIA; AMYLASE BLOOD LEVEL; ANXIETY DISORDER; APPETITE DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUDITORY HALLUCINATION; BREAST DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DEPRESSION; DIVERTICULITIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSLIPIDEMIA; EJACULATION DISORDER; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INJECTION SITE PAIN; INJECTION SITE SWELLING; INSOMNIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MOTOR DYSFUNCTION; MUSCULOSKELETAL STIFFNESS; NAUSEA; OTITIS MEDIA; PARANOID SCHIZOPHRENIA; PARKINSONISM; PERSECUTORY DELUSION; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; SUICIDAL IDEATION; SYNCOPE; TOOTH PAIN; TREATMENT OUTCOME; TREMOR; VOMITING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DOSE RESPONSE; INTRAMUSCULAR DRUG ADMINISTRATION; RISK; TIME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MALE; PALMITATES; RISK; SCHIZOPHRENIA; TIME FACTORS;

EID: 79955737767     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-79     Document Type: Article

References (17)

1. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2004, 161(2 Suppl):1-56. Second.
2. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005, 162(10):1785-1804. 10.1176/appi.ajp.162.10.1785, 16199825.
3. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002, 16(7):473-484. 10.2165/00023210-200216070-00004, 12056922.
4. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10:2. 10.1186/1471-244X-10-2, 2817695, 20059765.
5. Glick ID, Bossie CA, Alphs L, Canuso CM. Onset and persistence of antipsychotic response in patients with schizophrenia. J Clin Psychopharmacol 2009, 29(6):542-547. 10.1097/JCP.0b013e3181befa2a, 19910718.
6. INVEGA® SUSTENNA® (Paliperidone Palmitate) Package Insert. 2009, Janssen. Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
7. Samtani MH, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia. Clin Pharmacokinet 2009, 48(9):585-600. 10.2165/11316870-000000000-00000, 19725593.
8. Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin 2010, 26(2):377-387. 10.1185/03007990903482772, 20001492.
9. Gopal S, Hough D, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010, 25(5):247-256. 10.1097/YIC.0b013e32833948fa, 20389255.
10. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010, 116:107-117. 10.1016/j.schres.2009.10.026, 19959339.
11. Nasrallah H, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, Yuen E, Hough D. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacol 2010, 35:2072-2082.
12. Kramer M, Littman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010, 13(5):635-647. 10.1017/S1461145709990988, 19941696.
13. Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(6):1022-1031. 10.1016/j.pnpbp.2009.05.014, 19481579.
14. Pandina G, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumaker V, Yuen E, Palumbo J. A randomized, placebo-controlled study to assess the efficacy and safety of three doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010, 30(3):235-244. 10.1097/JCP.0b013e3181dd3103, 20473057.
15. Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, Simpson G. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(1):218-226. 10.1016/j.pnpbp.2010.11.008, 21092748.
16. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008, 23(Suppl 1):15-26.
17. Pierre J. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005, 28(3):191-208. 10.2165/00002018-200528030-00002, 15733025.